References
- Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363:2135–2144.
- Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res. 2014;41:1–25. doi:https://doi.org/10.1016/j.preteyeres.2014.04.001.
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:https://doi.org/10.1056/NEJMoa054481.
- Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113(10):1706–1712. doi:https://doi.org/10.1016/j.ophtha.2006.04.033.
- Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102–1112.e1. doi:https://doi.org/10.1016/j.ophtha.2010.02.021.
- Ehlers JP, Kim SJ, Yeh S, et al. Therapies for macular edema associated with branch retinal vein occlusion: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(9):1412–1423. doi:https://doi.org/10.1016/j.ophtha.2017.03.060.
- Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Exp Ophthalmol. 2008;246(9):1241–1247. doi:https://doi.org/10.1007/s00417-008-0866-8.
- Jaissle GB, Szurman P, Feltgen N, et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):183–192. doi:https://doi.org/10.1007/s00417-010-1470-2.
- Tomiyasu T, Hirano Y, Yoshida M, et al. Microaneurysms cause refractory macular edema in branch retinal vein occlusion. Sci Rep. 2016;6(1):29445. doi:https://doi.org/10.1038/srep29445.
- Tadayoni R, Waldstein SM, Boscia F, et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology. 2016;123(6):1332–1344. doi:https://doi.org/10.1016/j.ophtha.2016.02.030.
- Narayanan R, Panchal B, Das T, et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol. 2015;99(7):954–959. doi:https://doi.org/10.1136/bjophthalmol-2014-306543.
- Miwa Y, Muraoka Y, Osaka R, et al. Ranibizumab for macular edema after branch retinal vein occlusion: one initial injection versus three monthly injections. Retina. 2017;37(4):702–709. doi:https://doi.org/10.1097/IAE.0000000000001224.
- Yasuda Y, Hirano Y, Esaki Y, et al. Peripheral microvascular abnormalities detected by wide-field fluorescein angiography in eyes with branch retinal vein occlusion. Ophthalmic Res. 2019;61(2):107–114. doi:https://doi.org/10.1159/000488496.
- Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–809. doi:https://doi.org/10.1016/j.ophtha.2011.12.005.
- Tadayoni R, Waldstein SM, Boscia F, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of BRIGHTER study. Ophthalmology. 2017;S0161-6420:1–10.
- Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094–1101. doi:https://doi.org/10.1016/j.ophtha.2010.01.058.
- Kawamura M, Hirano Y, Yoshida M, et al. Six-month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study: visual outcomes and microaneurysm formation. Clin Ophthalmol. 2018;12:1487–1494. doi:https://doi.org/10.2147/OPTH.S170698.
- Hasegawa T, Takahashi Y, Maruko I, Kogure A, Iida T. Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion. Br J Ophthalmol. 2019;103(10):1367–1372. doi:https://doi.org/10.1136/bjophthalmol-2018-312769.
- Mir TA, Kherani S, Hafiz G, et al. Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion. Ophthalmology. 2016;123(3):625–634.e1. doi:https://doi.org/10.1016/j.ophtha.2015.10.030.
- Suzuki N, Hirano Y, Tomiyasu T, et al. Retinal hemodynamics seen on optical coherence tomography angiography before and after treatment of retinal vein occlusion. Invest Ophthalmol Vis Sci. 2016;57(13):5681–5687. doi:https://doi.org/10.1167/iovs-16-20648.
- Low A, Faridi A, Bhavsar KV, et al. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Br J Ophthalmol. 2019;103(4):442–451. doi:https://doi.org/10.1136/bjophthalmol-2018-312691.
- Spooner K, Hong T, Fraser-Bell S, Chang AA. Current outcomes of anti-VEGF therapy in the treatment of macular oedema secondary to branch retinal vein occlusions: a meta-analysis. Ophthalmologica. 2019;3:1–15.